Bristol Myers Squibb is growing key newer medicines and just picked up fresh approvals that could support the next leg of growth, even as overall profits swing around sharply. The big question is whether planned cost cuts and these launches can offset pressure on older drugs—or whether the stock is cheap for a reason.Read more

Medtronic looks like a steady medical-device business that may be overlooked, even as new products in robot-assisted surgery and diabetes care start to gain traction. The big question is whether it can turn its innovation pipeline into faster growth while navigating tough regulators, fierce rivals, and pricing pressure from hospitals.Read more